Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Scientific Correspondence
  • Published:

Association of a polymorphism in the promoter region of theserotonin 5-HT2Creceptor gene with tardive dyskinesia in patients with schizophrenia

Molecular Psychiatry volume 7, pages 670–671 (2002)Cite this article

SIR – Genetic factors are thought to contribute to susceptibility to develop tardive dyskinesia (TD), a major side effect of chronic antipsychotic drug treatment. As the 5-HT2C receptor is involved in motor function including the production of dyskinesias, and polymorphisms of the 5HT2C receptor promotor region with different promotor activities have been identified,1 we assessed the association with TD of two of these polymorphisms in Chinese schizophrenic patients.

Concordance for the presence or absence of TD between first-degree relatives receiving chronic neuroleptic treatment indicates the importance of genetic factors in this side effect.2 Pharmacogenetic association studies of TD have implicated several genes including, for example, those for the dopamine D3 receptor,3,4 CYP2D65 and 5-HT2A receptor.6 A further candidate gene is the 5-HT2C receptor. 5-HT2C antagonists reduce catalepsy induced by haloperidol7 and the orofacial dyskinesias elicited by 5-HT agonists injected into the rat subthalamic nucleus.8 One previous genetic study has reported a significant excess of the 5-HT2C 23Ser allele in female patients with orofacial TD.4 However, the scarcity of the 23Ser variant in a Chinese population9 suggests it is unlikely to contribute substantially to pharmacogenetic differences in this ethnic group.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Yuan X et al. Diabetologia 2000; 43: 373–376

  2. Youssef H et al. Int Clin Psychopharmacol 1989; 4: 323–328

  3. Steen VM et al. Mol Psychiatry 1997; 2: 139–145

  4. Segman RH et al. Psychopharmacology 2000; 152: 408–413

  5. Kapitany T et al. Schizophr Res 1998; 32: 101–106

  6. Tan E-C et al. Biol Psychiatry 2001; 50: 144–147

  7. Reavill C et al. Br J Pharmacol 1999; 126: 572–574

  8. Eberle-Wang K et al. Neuroscience 1996; 72: 117–128

  9. Hong CJ et al. Pharmacogenetics 2001; 11: 265–268

  10. Schooler NR, Kane JM . Arch Gen Psychiatry 1982; 39: 486–487

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Nanjing Brain Hospital and Nanjing Medical University, Nanjing, PR China

    Z-J Zhang, X-B Zhang & X-B Zhang

  2. Department of Biomedical Science, University of Sheffield, Sheffield, S10 2TN, UK

    Z-J Zhang & G P Reynolds

  3. Department of Psychiatry, Yangzhou WuTaiShan Hospital, JiangSu, PR China

    X-B Zhang & W-W Sha

Authors
  1. Z-J Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. X-B Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W-W Sha
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. X-B Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G P Reynolds
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G P Reynolds.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, ZJ., Zhang, XB., Sha, WW. et al. Association of a polymorphism in the promoter region of theserotonin 5-HT2Creceptor gene with tardive dyskinesia in patients with schizophrenia. Mol Psychiatry 7, 670–671 (2002). https://doi.org/10.1038/sj.mp.4001052

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.mp.4001052

This article is cited by

Search

Advanced search

Quick links